This project deals with the interactions between EBV-infected cells and the host immune system in normal and immunodefective persons. For an improved understanding of this complex system, it is necessary to broaden our knowledge both on the interaction of the virus with different host cells in vitro and in vivo, and on the interplay between the virally infected cells and the host. This project aims at the analysis of certain questions at both levels, in a mutually interrelated way. The project consists of the following parts: I. Analysis of the virus-cell-host system II. Clinically related studies. Part I will deal with: 1. Continued study of the six proteins now known to be associated with EBV-transformed B cells, EBNA-1-5 and LMP; 2. Phenotype related differences between LCL and BL subtypes and role of such differences for identifying the tumor precursor cell of origin, and for target cell sensitivity to MHC- restricted cytotoxic T-cells; 3. Effector mechanisms mediating immune surveillance against EBV transformed cells; 4. Some aspects of the EBV-B cell interaction. Part III will focus on: 1. Methodological developments aimed at the demonstration of latently EBV-infected cells in vivo; 2. Identification and characterization of EBV carrying B-cells in vivo; 3. Effector mobilization during acute mononucleosis, compared to silent seroconversion; 4. EBV specific and non specific effector analysis in immunodefectives that can or cannot control the proliferaton of latently EBV-infected B-cells; 5. Host- EBV-B cell relationships in patients with AIDS or AIDS-related complex (ARC); 6. Antigen expression studies in nasopharyngeal carcinoma.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA030264-07
Application #
3169160
Study Section
Experimental Immunology Study Section (EI)
Project Start
1981-09-01
Project End
1991-02-28
Budget Start
1988-03-01
Budget End
1989-02-28
Support Year
7
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Karolinska Institute
Department
Type
DUNS #
350582235
City
Stockholm
State
Country
Sweden
Zip Code
171 77
Contreras-Brodin, B; Karlsson, A; Nilsson, T et al. (1996) B cell-specific activation of the Epstein-Barr virus-encoded C promoter compared with the wide-range activation of the W promoter. J Gen Virol 77 ( Pt 6):1159-62
Chen, F; Hu, L F; Ernberg, I et al. (1995) Coupled transcription of Epstein-Barr virus latent membrane protein (LMP)-1 and LMP-2B genes in nasopharyngeal carcinomas. J Gen Virol 76 ( Pt 1):131-8
Stuber, G; Dillner, J; Modrow, S et al. (1995) HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1. Int Immunol 7:653-63
Lewin, N; Avila-Carino, J; Minarovits, J et al. (1995) Detection of two Epstein-Barr-virus (EBV)-carrying leukemic cell clones in a patient with chronic lymphocytic leukemia (CLL). Int J Cancer 61:159-64
Hu, L F; Chen, F; Zhen, Q F et al. (1995) Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas. Eur J Cancer 31A:658-60
Trivedi, P; Zhang, Q J; Chen, F et al. (1995) Parallel existence of Epstein-Barr virus (EBV) positive and negative cells in a sporadic case of Burkitt lymphoma. Oncogene 11:505-10
Chen, F; Zou, J Z; di Renzo, L et al. (1995) A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol 69:3752-8
Zheng, X; Yuan, F; Hu, L et al. (1994) Effect of beta-lymphocyte- and NPC-derived EBV-LMP1 gene expression on in vitro growth and differentiation of human epithelial cells. Int J Cancer 57:747-53
Avila-Carino, J; Lewin, N; Yamamoto, K et al. (1994) EBV infection of B-CLL cells in vitro potentiates their allostimulatory capacity if accompanied by acquisition of the activated phenotype. Int J Cancer 58:678-85
Masucci, M G; Ernberg, I (1994) Epstein-Barr virus: adaptation to a life within the immune system. Trends Microbiol 2:125-30

Showing the most recent 10 out of 87 publications